Cabergoline

Cabergoline Reactions 1680, p75 - 2 Dec 2017 Mania with psychotic features: case report A 22-year-old woman developed mania with psychotic features during treatment with cabergoline [Dostinex; route and dosage not stated]. The woman, who was diagnosed with infertility due to hyperprolactinaemia, presented to the psychiatric unit after four days of the first dose of cabergoline. Her family reported the changes in her behaviour, insomnia, self-talking, euphoria and false claims. A psychiatric evaluation revealed that she appeared euphoric and loudly-laughing with psychomotor hyperactivity, grandiose behaviour, flight of ideas and delusions of persecutions. Her mood was labile with impaired abstract, judgement and pressured speech. The young mania rating scale score was found to be 40. A diagnosis of mania with psychotic features was made. The woman’s cabergoline treatment was discontinued. She was successfully managed with aripiprazole and carbamazepine. Three weeks later, her manic symptoms improved with a resolution of her psychiatric symptoms. Author comment: "Hereby, we report a case of cabergoline-induced mania with psychotic features in a patient with hyperprolactinemia." Aziz MAE, et al. Mania-like symptoms induced by dopamine agonist treatment in a patient with hyperprolactinemia: A case report and a review of the literature. CNS Spectrums 22: 87-88 abstr. 145, No. 1, Feb 2017. Available from: URL: http://doi.org/10.1017/S1092852916000900 [abstract] - Egypt 803284814 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Cabergoline

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/cabergoline-qjlyMOZRYz
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39006-y
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial